Johnson & Johnson (NYSE:JNJ) has made impressive strides on the development of a COVID-19 vaccine. While the company was forced to halt trials after one of the volunteers developed an unknown illness, the company has confirmed plans to start testing the vaccine in children between 12 and 18 years.
Vaccine Testing On Kids
In a meeting held by the U.S Centers for Disease Control and Prevention, the company confirmed that it plans to test the vaccine in even younger children. However, the trials will depend on the safety and other factors. The company has already held discussions with regulators and partners as it sees the pediatric population's inclusion in the trials.
The Food and Drug Administration has already reiterated that drug makers working on the COVID-19 vaccine need to test them in Children. However, some doctors have raised concerns that the vaccines could end up triggering life-threatening conditions in some children.
Johnson & Johnson has already started testing the vaccine in 60,000 volunteers as part of Phase 3 trials. Trials resumed last week after coming to a halt after one of the volunteers had an adverse reaction. It is not the only company that is ramping up Phase 3 trials. Johnson & Johnson is the most important vaccine as testing is being carried out using a single dose.
COVID-19 Vaccine Development
Drug maker Pfizer Inc. (NYSE: PFE) has also begun testing its COVID-19 vaccine, which it is developing in partnership with Germany’s BionTech. The company has also started testing the vaccine in children as young as 12 years. Its vaccine leverages the new messenger RNA technology that is yet to produce an approved vaccine.
Johnson & Johnson COVID-19 vaccine uses a cold virus to deliver coronavirus genetic material, conversely triggering immune response. The technology has already been used with great success in the development of the Ebola vaccine approved in Europe earlier in the year.
AstraZeneca plc. (NASDAQ:AZN) is another company that has resumed trials for its COVID-19 vaccine. The company was forced to halt Phase 3 trials after one of the volunteers contracted a neurological condition.